The complement system is a network of over 30 soluble and membrane-bound proteins that constitute a major arm of innate immunity. In the brain, complement proteins are produced locally by astrocytes and microglia. Complement genes (CLU, CR1, C4A/C4B) are risk loci for Alzheimer's disease, positioning the complement system as both a biomarker and a therapeutic target in neurodegeneration. [1]
The complement system represents a critical pathological mechanism in neurodegenerative diseases, particularly Complement-Mediated Synapse Loss — the strongest pathological correlate of cognitive decline in Alzheimer's disease, exceeding even amyloid plaque burden and neurofibrillary tangle density. Originally discovered as a normal developmental pruning mechanism, inappropriate reactivation of complement-dependent synaptic elimination in the adult brain has emerged as a major contributor to cognitive decline in Alzheimer's disease, Huntington's Disease, multiple sclerosis, Frontotemporal Dementia, and other neurodegenerative conditions. [2]
The complement system consists of over 30 proteins that work in a cascade to eliminate pathogens and damaged cells. In the brain, complement is produced by neurons, astrocytes, and particularly microglia. Key triggers for complement activation in the brain include: [3]
C1q binding activates C1r/C1s proteases, which cleave C4 and C2 to form the classical C3 convertase (C4b2a). The classical pathway is the most relevant complement activation route in Alzheimer's Disease and developmental synaptic pruning. [4]
In Alzheimer's Disease, soluble amyloid-beta oligomers — rather than fibrillar plaques — are the primary trigger for aberrant C1q deposition on synapses. C1q protein levels are dramatically increased (up to 80-fold) in the AD hippocampus compared to age-matched controls, with increases detectable before visible plaque pathology. [5]
The complement system operates through three activation pathways that converge on a common terminal pathway:
Classical Pathway: Initiated by C1q binding to antigen-antibody complexes, damaged cell surfaces, or amyloid-beta oligomers. C1q recruits C1r and C1s, forming the C1 complex, which then cleaves C4 and C2 to generate the C3 convertase C4b2a.
Lectin Pathway: Triggered by mannose-binding lectin (MBL) and ficolins recognizing carbohydrate patterns on damaged cells and pathogens. MBL-associated serine proteases (MASP-1, MASP-2) cleave C4 and C2, generating the same C3 convertase as the classical pathway.
Alternative Pathway: Constitutively active at low levels through spontaneous C3 hydrolysis ("tickover"). C3b deposited on surfaces recruits factor B, which is cleaved by factor D to form the alternative C3 convertase (C3bBb), amplified by properdin.
All three pathways converge at C3 cleavage, which generates: [6]
The terminal pathway continues from C5 cleavage to form C5b-9, the membrane attack complex (MAC), which can directly lyse cells or cause sublytic damage.
| Component | Type | Primary Function |
|---|---|---|
| C1q, C1r, C1s | Recognition/Enzyme | Classical pathway initiation |
| C4 | Zymogen | Pathway convergence |
| C2 | Zymogen | C3 convertase formation |
| C3 | Central component | Opsonization, anaphylatoxin generation |
| Factor B, D, P | Alternative pathway | Amplification loop |
| C5 | Terminal pathway | Inflammatory mediator generation |
| C6, C7, C8, C9 | Terminal pathway | MAC formation |
| C3a, C5a | Anaphylatoxins | Inflammation recruitment |
| C3b, iC3b, C4b | Opsonins | Phagocytic recognition |
During normal brain development, complement eliminates excess synapses to refine neural circuits. C1q localizes to weaker or less active synapses, triggers C3 activation, and C3b/iC3b deposition opsonizes those synapses for microglial phagocytosis via CR3. This process is essential for proper circuit maturation — C1q or C3 knockout mice retain excess retinogeniculate synapses. [7]
The developmental pruning process involves several key steps:
This developmental process is carefully regulated — excessive pruning can lead to connectivity deficits, while insufficient pruning can result in improper circuit formation.
In the adult brain, the developmental pruning pathway is normally downregulated. However, it becomes aberrantly reactivated in neurodegenerative diseases: [8]
The reactivation of synaptic pruning represents a pathological continuum from developmental physiology to neurodegenerative disease. Key factors driving this reactivation include:
The complement-mediated synaptic elimination process involves sophisticated molecular recognition:
C1q binding targets: C1q binds to multiple synaptic surface molecules, including:
C3b/iC3b deposition patterns: The density and pattern of complement deposition determines phagocytic susceptibility:
Microglial CR3 signaling: CR3 (CD11b/CD18) engagement triggers:
Emerging evidence links complement to tau pathology: [9]
The relationship between complement and tau creates a vicious cycle:
Complement activation mirrors the topographic pattern of early AD, with the hippocampus, entorhinal cortex, and prefrontal cortex showing the highest complement burden. This region-specific pattern corresponds to the areas most vulnerable to early synaptic loss.
The selective vulnerability of these regions reflects:
APOE4 enhances complement activation in the brain:
The APOE4-complement interaction provides a mechanistic explanation for the increased Alzheimer's risk in APOE4 carriers. Strategies to normalize this interaction could provide therapeutic benefit.
TREM2 — an AD risk gene expressed on microglia — plays a critical role in the microglial response to complement-tagged synapses. TREM2 deficiency impairs microglial phagocytosis of complement-opsonized synapses, potentially contributing to synaptic loss in AD.
The TREM2-CR3 interaction in synaptic pruning:
Key complement regulatory proteins in the brain include:
Dysregulation of these regulators contributes to pathological complement activation. In AD, decreased expression of CD55 and CD59 has been observed, reducing the "braking" capacity on complement cascades.
C1q and C3 are upregulated in the substantia nigra in Parkinson's disease, and alpha-synuclein aggregates activate the classical complement pathway. C4 exacerbates astrocyte-mediated neuroinflammation and promotes dopaminergic neuron loss. C3aR and C5aR1 signaling contribute to dopaminergic neuron loss, and CR3 knockout mice are protected from toxin-induced parkinsonism. [11]
Key mechanisms in Parkinson's disease:
Huntington's Disease features early complement-mediated synapse loss in the corticostriatal circuit. C1q and C3 are elevated in the striatum of HD patients and mouse models. [12]
Complement in Huntington's disease:
In ALS, complement activation occurs at the neuromuscular junction and in spinal motor neurons. C1q, C3, and MAC are deposited at motor endplates before symptom onset in SOD1 mouse models. The C5aR1 antagonist PMX205 extends survival and improves motor function in ALS models.
Complement in ALS:
In multiple sclerosis and other demyelinating diseases, complement-mediated synapse loss occurs at demyelinated lesions. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease models.
Complement in MS:
Complement activation drives synaptic loss in FTD models, particularly those involving tau pathology and TDP-43 proteinopathy. C1q-dependent astrocyte and microglial synapse elimination has been demonstrated in tau transgenic models relevant to FTD.
C1q inhibition represents the most upstream approach to blocking pathological complement activation while preserving some normal complement function.
C3 inhibition blocks all downstream complement effects but carries higher infection risk due to complete opsonin loss.
Blocking the microglial complement receptor CR3 directly prevents phagocytic engulfment of complement-tagged synapses. CR3 knockout mice are protected from amyloid-beta-induced synapse loss.
| Agent | Target | Company | Status | Indication |
|---|---|---|---|---|
| ANX005 | C1q | Annexon | Phase 2 | Huntington's, ALS |
| Pegcetacoplan | C3 | Apellis | Phase 1 (CNS) | AMD, AD |
| Eculizumab | C5 | Alexion | Approved | PNH, aHUS |
| Avacopan | C5aR1 | ChemoCentryx | Approved | Vasculitis |
Complement-mediated synapse loss intersects with multiple pathological pathways in neurodegeneration:
Complement activation products in cerebrospinal fluid and plasma show promise as neurodegeneration biomarkers:
Even in the absence of neurodegenerative disease, complement activity increases with age. This age-related " complementopathy" may contribute to:
The aging brain shows:
This normal aging context helps explain why late-onset neurodegenerative diseases are more prevalent and suggests that complement modulation could have benefits even in normal aging.
Gene Expression Databases:
Beyond its pathological role in neurodegeneration, the complement system participates in several normal brain functions:
Recent research reveals that complement proteins modulate synaptic plasticity in the adult brain:
Complement serves as a communication system between glia and neurons:
The complement system provides constant immune surveillance:
Genome-wide association studies have identified several complement-related genetic variants affecting neurodegenerative disease risk:
Key findings from complement research in animal models:
Research directions with potential for clinical translation include:
Chen WT et al. Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease (2020). 2020. ↩︎
Zhao H et al. The activation of microglia by the complement system in neurodegenerative diseases (2025). 2025. ↩︎
Fatoba O, Itokazu T, Yamashita T, Complement cascade functions during brain development and neurodegeneration (2022). 2022. ↩︎
Stephan AH et al. The complement system: An unexpected role in synaptic pruning during development and disease (2013). 2013. ↩︎
Hong S et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models (2016). 2016. ↩︎
Jovčevska I et al. Complement Cascades and Brain Disorders (2025). 2025. ↩︎
Savage JC et al. Microglial ultrastructure in the aging brain (2022). 2022. ↩︎
Clarke BE et al. Astrocyte contributions to synapse elimination in the developing brain (2023). 2023. ↩︎
Lippens A et al. TIMP-1 protects against complement-mediated synapse loss in Alzheimer's disease (2024). 2024. ↩︎
Zhao Y et al. APOE and complement in Alzheimer's disease (2020). 2020. ↩︎
Wilton DK et al. Complement and microglia in Parkinson's disease (2020). 2020. ↩︎
Singh M et al. Complement in Huntington's disease (2023). 2023. ↩︎